Literature DB >> 17349698

The Akt-GSK-3 signaling cascade in the actions of dopamine.

Jean-Martin Beaulieu1, Raul R Gainetdinov, Marc G Caron.   

Abstract

Drugs that act on dopamine neurotransmission are important tools for the management of multiple neuropsychiatric disorders. Classically, dopamine receptors have been shown to regulate cAMP-PKA (protein kinase A) and Ca(2+) pathways through G-protein-mediated signaling. However, it has become apparent that, in addition to this canonical action, D(2)-class dopamine receptors can function through a protein kinase B (Akt)-GSK-3 (glycogen synthase kinase 3) signaling cascade. This novel signaling mode involves the multifunctional scaffolding protein beta-arrestin 2, which has a role in G-protein-coupled receptor (GPCR) desensitization. In this article, we provide an overview of how this dual function of components of the GPCR desensitization machinery relates to dopamine-receptor-mediated responses and we summarize recent insights into the relevance of the Akt-GSK-3 signaling cascade for the expression of dopamine-associated behaviors and the actions of dopaminergic drugs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349698     DOI: 10.1016/j.tips.2007.02.006

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  157 in total

1.  Ethanol-induced activation of AKT and DARPP-32 in the mouse striatum mediated by opioid receptors.

Authors:  Karl Björk; Anton Terasmaa; Hui Sun; Annika Thorsell; Wolfgang H Sommer; Markus Heilig
Journal:  Addict Biol       Date:  2010-04-29       Impact factor: 4.280

2.  PINK1 enhances insulin-like growth factor-1-dependent Akt signaling and protection against apoptosis.

Authors:  Ravi S Akundi; Lianteng Zhi; Hansruedi Büeler
Journal:  Neurobiol Dis       Date:  2011-09-16       Impact factor: 5.996

Review 3.  Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders.

Authors:  K Fuxe; D Marcellino; D O Borroto-Escuela; M Guescini; V Fernández-Dueñas; S Tanganelli; A Rivera; F Ciruela; L F Agnati
Journal:  CNS Neurosci Ther       Date:  2010-03-16       Impact factor: 5.243

Review 4.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

Review 5.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

Review 6.  Insulin signaling and addiction.

Authors:  Lynette C Daws; Malcolm J Avison; Sabrina D Robertson; Kevin D Niswender; Aurelio Galli; Christine Saunders
Journal:  Neuropharmacology       Date:  2011-03-21       Impact factor: 5.250

7.  Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.

Authors:  Nikhil M Urs; Simone Bido; Sean M Peterson; Tanya L Daigle; Caroline E Bass; Raul R Gainetdinov; Erwan Bezard; Marc G Caron
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-27       Impact factor: 11.205

8.  Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex.

Authors:  Yan-Chun Li; Dong Xi; Joy Roman; Yue-Qiao Huang; Wen-Jun Gao
Journal:  J Neurosci       Date:  2009-12-09       Impact factor: 6.167

9.  Genetic Disruption of Arc/Arg3.1 in Mice Causes Alterations in Dopamine and Neurobehavioral Phenotypes Related to Schizophrenia.

Authors:  Francesca Managò; Maddalena Mereu; Surjeet Mastwal; Rosa Mastrogiacomo; Diego Scheggia; Marco Emanuele; Maria A De Luca; Daniel R Weinberger; Kuan Hong Wang; Francesco Papaleo
Journal:  Cell Rep       Date:  2016-08-11       Impact factor: 9.423

10.  Recruitment of beta-arrestin2 to the dopamine D2 receptor: insights into anti-psychotic and anti-parkinsonian drug receptor signaling.

Authors:  Ib V Klewe; Søren M Nielsen; Louise Tarpø; Eneko Urizar; Concetta Dipace; Jonathan A Javitch; Ulrik Gether; Jan Egebjerg; Kenneth V Christensen
Journal:  Neuropharmacology       Date:  2008-04-08       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.